These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32760858)

  • 1. Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation.
    Pavo IJ; Pavo N; Kastner N; Traxler D; Lukovic D; Zlabinger K; Spannbauer A; Riesenhuber M; Lorant D; Bartko PE; Goliasch G; Hülsmann M; Winkler J; Gyöngyösi M
    JACC Basic Transl Sci; 2020 Jul; 5(7):715-726. PubMed ID: 32760858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin Inhibitors in Heart Failure: The Science, Mechanism of Action, Clinical Studies, and Unanswered Questions.
    Bozkurt B; Nair AP; Misra A; Scott CZ; Mahar JH; Fedson S
    JACC Basic Transl Sci; 2023 Jan; 8(1):88-105. PubMed ID: 36777165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
    Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failure.
    Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Mascherbauer J; Haslacher H; Strunk G; Hülsmann M; Pavo N
    ESC Heart Fail; 2021 Jun; 8(3):2016-2024. PubMed ID: 33742565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease.
    Chen Y; Burnett JC
    Clin Chem; 2017 Jan; 63(1):108-115. PubMed ID: 28062615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
    J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Type Natriuretic Peptide (BNP) Revisited-Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
    Nishikimi T; Nakagawa Y
    Biology (Basel); 2022 Jul; 11(7):. PubMed ID: 36101415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of BNP and Sacubitrilat/Valsartan on Atrial Functional Reserve and Arrhythmogenesis in Human Myocardium.
    Primessnig U; Deißler PM; Wakula P; Tran KL; Hohendanner F; von Lewinski D; Blaschke F; Knosalla C; Falk V; Pieske B; Grubitzsch H; Heinzel FR
    Front Cardiovasc Med; 2022; 9():859014. PubMed ID: 35865376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
    Feygina EE; Artemieva MM; Postnikov AB; Tamm NN; Bloshchitsyna MN; Medvedeva NA; Katrukha AG; Semenov AG
    Clin Chem; 2019 Oct; 65(10):1239-1247. PubMed ID: 31307994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal muscle alterations in tachycardia-induced heart failure are linked to deficient natriuretic peptide signalling and are attenuated by RAS-/NEP-inhibition.
    Dietl A; Winkel I; Pietrzyk G; Paulus M; Bruckmann A; Schröder JA; Sossalla S; Luchner A; Maier LS; Birner C
    PLoS One; 2019; 14(12):e0225937. PubMed ID: 31800630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of renal neutral endopeptidase in severe heart failure.
    Knecht M; Pagel I; Langenickel T; Philipp S; Scheuermann-Freestone M; Willnow T; Bruemmer D; Graf K; Dietz R; Willenbrock R
    Life Sci; 2002 Oct; 71(23):2701-12. PubMed ID: 12383878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights from Indian Cardiologists.
    Dalal J; Chandra P; Ray S; Hazra PK; Hiremath J; Kumar V; Shah MK; Abdullakutty J; Ghosh D; Vasudevan K; Sahoo P
    Cardiol Ther; 2023 Sep; 12(3):445-471. PubMed ID: 37382802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases.
    Nakagawa H; Saito Y
    Biology (Basel); 2022 Jul; 11(7):. PubMed ID: 36101398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and diagnostics in heart failure.
    Gaggin HK; Januzzi JL
    Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP.
    Bayes-Genis A; Barallat J; Galán A; de Antonio M; Domingo M; Zamora E; Gastelurrutia P; Vila J; Peñafiel J; Gálvez-Montón C; Lupón J
    Rev Esp Cardiol (Engl Ed); 2015 Dec; 68(12):1075-84. PubMed ID: 26297179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase.
    Wang Y; Moreira Mda C; Heringer-Walther S; Schultheiss HP; Siems WE; Wessel N; Walther T
    J Cardiovasc Pharmacol; 2010 Jan; 55(1):62-6. PubMed ID: 20090473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure.
    Maki T; Nasa Y; Yamaguchi F; Yoshida H; Mori M; Takada T; Horikawa E; Okano K; Takeo S
    Cardiovasc Res; 2001 Aug; 51(3):608-17. PubMed ID: 11476752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.